IP Library Granted Patent US 11,618,748
Granted Patent B2
US 11,618,748 · App. 17/243,272 · Granted Apr 4, 2023

Dual mechanism inhibitors for the treatment of disease

Inventors: Mitchell A. deLong (Chapel Hill, NC); Jill Marie Sturdivant (Chapel Hill, NC); Susan M. Royalty (Davis, CA)
Assignee: Aerie Pharmaceuticals, Inc.
C07D417/12C07C237/20C07C237/42C07D217/00C07D217/02C07D217/04C07D217/22C07D217/24C07D333/38C07D333/40C07D401/12C07D405/12C07D409/12C07D413/12C07C2601/08C07C2601/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,618,748
App. No.
17/243,272
Granted
Apr 4, 2023
Kind
B2
Abstract

Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.

Claims (38)

1. A method of reducing intraocular pressure, comprising administration of a composition comprising a Rho kinase inhibitor and a pharmaceutically acceptable carrier to a subject in need thereof,

wherein the administration is daily administration, weekly administration, or monthly administration,

wherein the Rho kinase inhibitor is:

or a pharmaceutically acceptable salt thereof,

wherein

R 1 , R 2 , and R 3 are independently hydrogen, C 1 -C 4 alkyl, aryl, C 1 -C 4 alkyl aryl, C 1 -C 4 alkyl heteroaryl, C 1 -C 4 alkyl heterocyclyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 carbonyl, C 1 -C 4 carbonylamino, C 1 -C 4 alkoxy, C 1 -C 4 sulfonyl, C 1 -C 4 sulfonylamino, C 1 -C 4 thioalkyl, C 1 -C 4 carboxyl, or form a ring with each other or with A;

A is C 1 -C 4 alkyl, C 1 -C 4 alkyl aryl, C 1 -C 4 alkyl heteroaryl, or forms a ring structure with R 1 , R 2 or R 3 ;

B is hydrogen, an aryl group, a heteroaryl group, a cycloalkyl group, a heterocycloalkyl group, C 1 -C 22 alkyl, C 1 -C 22 alkyl aryl, C 1 -C 22 alkyl heteroaryl, C 2 -C 22 alkenyl, C 2 -C 22 alkynyl, C 1 -C 22 carbonyl, C 1 -C 22 carbonylamino, C 1 -C 22 alkoxy, C 1 -C 22 sulfonyl, C 1 -C 22 sulfonylamino, C 1 -C 22 thioalkyl, or C 1 -C 22 carboxyl;

X 1 , X 2 , and X 3 are, independently, hydrogen, hydroxyl, halogen, C 1 -C 4 alkyl, C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, amino, aminocarbonyl, nitro, cyano, C 1 -C 4 carbonyl, C 1 -C 4 carbonylamino, C 1 -C 4 alkoxy, C 1 -C 4 sulfonyl, C 1 -C 4 sulfonylamino, C 1 -C 4 thioalkyl, or C 1 -C 4 carboxyl;

the double circle

indicates an aromatic or heteroaromatic ring; and

each Z is independently a bond, C 1 -C 4 alkyl, heteroalkyl, or an O atom.

2. The method of claim 1 , wherein the administration is ocular administration.

3. The method of claim 1 , wherein the amount of the compound administered is about 0.001 to about 100 mg/kg subject body weight.

4. The method of claim 1 , wherein the administration is once daily, twice per day, or 4 times per day.

5. The method of claim 2 , wherein the administration is once daily, twice per day, or 4 times per day.

6. The method of claim 3 , wherein the administration is once daily, twice per day, or 4 times per day.

7. The method of claim 1 , wherein the administration is once weekly or twice weekly.

8. The method of claim 2 , wherein the administration is once weekly or twice weekly.

9. The method of claim 3 , wherein the administration is once weekly or twice weekly.

10. The method of claim 1 , wherein the administration is once a month.

11. The method of claim 2 , wherein the administration is once a month.

12. The method of claim 3 , wherein the administration is once a month.

13. A method of treating glaucoma or ocular hypertension, comprising administration of a composition comprising a Rho kinase inhibitor and a pharmaceutically acceptable carrier to a subject in need thereof,

wherein the administration is daily administration, weekly administration, or monthly administration,

wherein the Rho kinase inhibitor is:

or a pharmaceutically acceptable salt thereof.

14. The method of claim 13 , wherein the administration is ocular administration.

15. The method of claim 13 , wherein the amount of the compound administered is about 0.001 to about 100 mg/kg subject body weight.

16. The method of claim 13 , wherein the administration is once daily, twice per day, or 4 times per day.

17. The method of claim 14 , wherein the administration is once daily, twice per day, or 4 times per day.

18. The method of claim 15 , wherein the administration is once daily, twice per day, or 4 times per day.

19. The method of claim 13 , wherein the administration is once weekly or twice weekly.

20. The method of claim 14 , wherein the administration is once weekly or twice weekly.

21. The method of claim 15 , wherein the administration is once weekly or twice weekly.

22. The method of claim 13 , wherein the administration is once a month.

23. The method of claim 14 , wherein the administration is once a month.

24. The method of claim 15 , wherein the administration is once a month.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2024
From: AERIE PHARMACEUTICALS, INC.
To: ALCON INC.
Reel/Frame 067822/0168 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2021
From: DELONG, MITCHELL A.; STURDIVANT, JILL MARIE; ROYALTY, SUSAN M.
To: AERIE PHARMACEUTICALS, INC.
Reel/Frame 056074/0486 →